Ask AI
ProCE Banner Activity

Translating Evidence to Action in Relapsed ES-SCLC: Integrating New Targeted Agents Into Clinical Practice

Slideset

Download these slides to explore current and emerging treatment strategies for patients with relapsed extensive-stage small-cell lung cancer (ES-SCLC). This module highlights recent advances in the use of targeted and immune-based therapies, with practical guidance on optimizing maintenance approaches, managing relapse, and integrating novel agents into evolving treatment pathways.

Released: November 25, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for medical oncologists, physician associates, and other healthcare professionals caring for patients with SCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Align SCLC clinical practice with updated practice guidelines for the treatment of limited-stage and extensive-stage disease

  • Integrate newer treatment strategies for limited- and extensive-stage SCLC into clinical practice, using best practices and an individualized approach